AstraZeneca Partners with Revna Biosciences to Enhance Epidermal Growth Factor Receptor (EGFR) Biomarker Testing in Ghana
EGFR Testing
Epidermal Growth Factor Receptor (EGFR) is a protein involved in cell growth, division and survival. Mutations in the EGFR gene lead to the over-production of EGFR proteins on some types of cancer cells, causing the cells to divide more rapidly.
EGFR is regarded as the cancer driver gene in lung cancer, particularly non-small cell lung cancer (NSCLC), and serves as a biomarker in cancer treatment. Accurate testing for EGFR mutations allows doctors to determine the best course of treatment for patients, including the use of targeted therapies that have shown greater efficacy and fewer side effects than traditional chemotherapy.
Today's Patient, Tomorrow's Hope
Dr. Khomotso Mashilane, Medical Director African Cluster at AstraZeneca remarked on the program's potential impact: 'At AstraZeneca, we are committed to working collaboratively with governments, healthcare professionals, and patient communities to create resilient healthcare systems and expand access to innovative cancer treatments for patients across Africa. By investing in EGFR biomarker testing and precision medicine, we are taking a pivotal step toward giving patients in Ghana the treatments they need and deserve. Today's patients are at the heart of our work, and with tomorrow's advances in targeted therapies, we are confident that hope will become a tangible reality for many.'
The first step in this collaboration is to map and streamline the patient journey from accurate diagnosis through treatment for improved health outcomes. Beyond providing advanced biomarker testing resource, this partnership will offer educational programs and workshops to equip healthcare professionals in the lung cancer space with next-generation tools, aiming for earlier detection and better clinical outcomes, ultimately contributing to global cancer control.
We anticipate initiating the rollout process shortly, which will encompass onboarding of participating healthcare professionals, the commencement of the first series of workshops, and participant selection.
Future Look
Dr. Derrick Edem Akpalu, CEO and Co-Founder of Revna Biosciences also spoke about the importance of the partnership 'This collaboration is timely, as the demand for personalized healthcare is growing. Advances in EGFR testing and targeted therapies offer unprecedented hope for improved cancer care in Ghana. Together, we aim to raise awareness and increase access to life-saving treatments, ensuring that every patient in Ghana has the best chance to thrive. The knowledge we gain today will help shape a better tomorrow for patients here and around the world."
Distributed by APO Group on behalf of Revna Biosciences.
About AstraZeneca:
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. The business is organized to deliver growth through innovation strategy and achieve the purpose of pushing the boundaries of science to deliver life-changing medicines in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases.
Inspired by values and what science can do, AstraZeneca is focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society and shareholders. They are committed to operating sustainably, in a way that recognizes the interconnection between business growth, the needs of society and the limitations of the planet.
About Revna Biosciences:
With an operational base in Accra, Ghana, and serving across West Africa, Revna Biosciences (RevnaBio) is a biomedical company committed to advancing molecular diagnostics and therapeutic discovery. With a mission to champion precision medicine for all, RevnaBio is devoted to unraveling the biological underpinnings of diseases affecting Africans, people of African descent, and the global population.
RevnaBio offers a comprehensive suite of services, including advanced molecular diagnostics, biobanking, biomarker exploration, clinical research, central lab services, disease monitoring, treatment selection, and trial management. Through strategic alliances with international biotech leaders such as QIAGEN, Diatech Pharmacogenetics, ABL Diagnostics, and Idil Biotech, RevnaBio delivers cutting-edge biomedical services in the heart of West Africa.
RevnaBio holds all necessary local permits and licenses, including the Health Facilities Regulatory Authority (HeFRA) permit for tertiary laboratories. RevnaBio has the approval of Ghana's Food&Drugs Authority (FDA), is dual ISO accredited (ISO 15189:2022; ISO 20387:2018) by the American Association for Laboratory Accreditation (A2LA) and a member of the International Society of Biological and Environmental Repositories (ISBER).
For more information about Revna Biosciences and its groundbreaking work in precision medicine, please contact +233-59-900-9977 or visit www.RevnaBio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
2 days ago
- Al Etihad
Sheikh Shakhbout Medical City and AstraZeneca launch an asthma inhaler recycling initiative
7 July 2025 18:25 ABU DHABI (ALETIHAD)Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the UAE for severe and complex care and a subsidiary of the PureHealth group, has today announced its collaboration with global biopharmaceutical company AstraZeneca to launch the 'Pure Air Solution' (PAS) partnership, formalised through a Memorandum of Understanding (MoU), focuses on the recycling of asthma inhalers. While demonstrating a shared commitment to sustainable healthcare practices, this initiative also addresses the urgent need to reduce the healthcare sector's carbon footprint, which currently contributes to approximately 5% of the world's greenhouse gas (GHG) emissions. Commenting on the launch of the initiative, Dr. Marwan Al Kaabi, chief executive officer at SSMC, said: 'By implementing a comprehensive inhaler recycling programme, SSMC and AstraZeneca are taking a significant step towards mitigating environmental harm, which aligns with the UAE's vision for net-zero carbon emissions by 2050.'Through the strategic placement of collection bins across SSMC's key clinics and pharmacies, the initiative will encourage asthma patients to participate in inhaler recycling. The partnership will also prioritise robust educational campaigns on asthma management and the importance of recycling, empowering both patients and staff at SSMC to engage in responsible disposal Al Kaabi added, 'The PAS initiative is further testament to SSMC's leadership in proactive environmental stewardship within the healthcare sector. By launching this programme, we are taking decisive strides towards a healthier, more sustainable future, while setting a precedent and establishing a benchmark for responsible healthcare practices within the region.'Sameh El Fangary, cluster president for GCC and Pakistan at AstraZeneca, shared: 'Partnering with SSMC reflects our shared commitment to advancing innovative and sustainable respiratory care. This collaboration aims to reduce the environmental impact associated with inhaler use, aligning with our integrated approach to health, addressing both patient outcomes and environmental considerations.'Project leads Dr. Haytham Shahata, research clinical pharmacist, and Dr. Lubna Issa, drug store operations manager at SSMC, said: 'Inhalers, among the most prevalent medical devices used in the UAE, account for nearly 80% of inhaler-related GHG output.1 This is largely attributable to hydrofluorocarbon propellants, which are up to 2,500 times more potent than carbon dioxide and can remain in the atmosphere for over 200 years.2,3 With 96% of an inhaler's climate impact stemming from these potent emissions, the PAS initiative is designed to significantly minimise the carbon footprint of respiratory care.4' The PAS initiative reinforces the power of collaborative innovation in building a sustainable healthcare ecosystem. By fostering a culture of recycling and education, SSMC and AstraZeneca are taking the lead in advancing sustainable healthcare practices across the UAE, ultimately benefiting patients and the broader community by ensuring long-term health and environmental well-being.
Zawya
3 days ago
- Zawya
Sheikh Shakhbout Medical City and AstraZeneca launch an asthma inhaler recycling initiative
Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the UAE for serious and complex care and a subsidiary of the PureHealth group, has today announced its collaboration with global biopharmaceutical company AstraZeneca, to launch the 'Pure Air Solution' (PAS) initiative. This partnership, formalised through a Memorandum of Understanding (MoU), focuses on the recycling of asthma inhalers. While demonstrating a shared commitment to sustainable healthcare practices, this initiative also addresses the urgent need to reduce the healthcare sector's carbon footprint, which currently contributes to approximately 5% of the world's greenhouse gas (GHG) emissions. Commenting on the launch of the initiative, Dr. Marwan Al Kaabi, chief executive officer at SSMC, said: 'By implementing a comprehensive inhaler recycling programme, SSMC and AstraZeneca are taking a significant step towards mitigating environmental harm, which aligns with the UAE's vision for net-zero carbon emissions, by 2050.' Through the strategic placement of collection bins across SSMC's key clinics and pharmacies, the initiative will encourage asthma patients to participate in inhaler recycling. The partnership will also prioritise robust educational campaigns on asthma management and the importance of recycling – empowering both patients and staff at SSMC to engage in responsible disposal practices. Dr. Al Kaabi, added: 'The PAS initiative is further testament to SSMC's leadership in proactive environmental stewardship within the healthcare sector. By launching this programme, we are taking decisive strides towards a healthier, more sustainable future, while setting a precedent and establishing a benchmark for responsible healthcare practices, within the region.' Sameh El Fangary, cluster president for GCC and Pakistan at AstraZeneca, shared: 'Partnering with SSMC reflects our shared commitment to advancing innovative and sustainable respiratory care. This collaboration aims to reduce the environmental impact associated with inhaler use, aligning with our integrated approach to health—addressing both patient outcomes and environmental considerations.' Project leads Dr. Haytham Shahata, research clinical pharmacist, and Dr. Lubna Issa, drug store operations manager at SSMC, said: 'Inhalers, among the most prevalent medical devices used in the UAE, account for nearly 80% of inhaler-related GHG output.1 This is largely attributable to hydrofluorocarbon propellants, which are up to 2,500 times more potent than carbon dioxide and can remain in the atmosphere for over 200 years.2,3 With 96% of an inhaler's climate impact stemming from these potent emissions, the PAS initiative is designed to significantly minimise the carbon footprint of respiratory care.4' The PAS initiative reinforces the power of collaborative innovation in building a sustainable healthcare ecosystem. By fostering a culture of recycling and education, SSMC and AstraZeneca are taking the lead in advancing sustainable healthcare practices across the UAE, ultimately benefiting patients and the broader community by ensuring long-term health and environmental well-being. For media inquiries, please contact: Fadya Al Kathairi Sheikh Shakhbout Medical City Email: falkathairi@ Afaf El-Sharkawy 9Yards Communications Email: References Alzaabi A, Bell JP, Montero-Arias F, et al. Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study. Adv Ther. 2023;40(11):4836-4856. doi:10.1007/s12325-023-02663-2. Jeswani HK, Azapagic A. Life cycle environmental impacts of inhalers. J Clean Prod. 2019;237:117733. doi:10.1016/ Borgford-Parnell N, Beaugrand M, Andersen SO, Zaelke D. Phasing Down the Use of Hydrofluorocarbons (HFCs). Contrib Pap Seiz Glob Oppor Partnersh Better Growth Better Clim. New Clim Econ. 2015. PSNC Briefing 024.21. Reducing the climate change impact of inhalers: environmentally safe disposal. August 2021. About Sheikh Shakhbout Medical City (SSMC) Sheikh Shakhbout Medical City is one of the largest tertiary hospitals in the UAE offering the highest standards of medical expertise for the treatment of serious and complex conditions. Established in 2019, SSMC has 660 patient beds, 18 operating theatres, including a hybrid operating room and a 26-bed neonatal intensive care unit. Supported by the latest diagnostic and treatment modalities available, SSMC offers care in 46 specialties, bringing advanced and trusted quality care closer to the UAE and the wider region. For more information on Sheikh Shakhbout Medical City or to book an appointment, please visit: About PureHealth PureHealth is the largest healthcare group in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 100+ hospitals, 300+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more, its groundbreaking innovations are at the forefront of healthcare as the company is on a mission to unlock time for humankind. By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth's network comprises: SEHA – One of the largest healthcare networks of hospitals and clinics in the UAE SEHA CLINICS - Delivering comprehensive community-based healthcare services Daman (The National Health Insurance Company) – The UAE's leading health insurer The Medical Office – Overseeing Sheikh Khalifa Hospitals and healthcare facilities established under the initiatives of H.H. The President of the UAE Rafed – The UAE's largest healthcare Group Purchasing Organisation PureLab – Managing and operating the largest network of laboratories in the region One Health – A network that provides end-to-end medical solutions to a base of over 300 healthcare service providers The Life Corner – Abu Dhabi's first holistic pharmacy, serving the health and wellness establishment Ardent Health Services – The fourth largest privately held acute care hospital operator in the US Circle Health Group – The largest independent operators of hospitals in the UK Hellenic Healthcare Group (HHG) - the largest private healthcare provider in Greece and Cyprus PureCS - A leading cloud and technology services provider, specialising in IT management and consulting solutions, cybersecurity, cloud services and AI information systems Sheikh Shakhbout Medical City (SSMC) – The UAE's largest healthcare complex, delivering integrated complex care To learn more, please visit
Zawya
03-06-2025
- Zawya
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
